Delivra Corp., a specialty biotechnology company, develops transdermal delivery system platform that shuttles pharmaceutical and natural molecules through the skin.
The last earnings update was 12 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Delivra is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Delivra has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Delivra. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Delivra's earnings available for a low price, and how does
this compare to other companies in the same industry?
Delivra has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of 9DV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Delivra's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Delivra has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Delivra's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Delivra's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Delivra's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Delivra is high growth as no earnings estimate data is available.
Unable to determine if Delivra is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Delivra's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Joseph Gabriele, also known as Joe has been the Chief Executive Officer and Chief Science Officer of Delivra Corp. since December 21, 2015. Dr. Gabriele is the Founder, Inventor and visionary behind the DelivraTM technology. Dr. Gabriele has devoted the past eight years to innovation, development and commercialization activities at Delivra. He has a doctorate in molecular pharmacology and is an Assistant Professor (PT), McMaster University, Department of Psychiatry and Behavioral Neurosciences, as well as Special Graduate Faculty, University of Guelph, Department of Biomedical Sciences. He served as Chief Executive Officer and Chief Science Officer at Delivra Inc. from July 2007 to December 2015. He served as Chief Executive Officer and President of Whiteknight Acquisitions III Inc., since December 21, 2015. He serves as Chairman at Delivra Corp. He has received numerous awards, including a CIHR studentship award in pharmacology during his M.Sc. degree; NSERC Canada Graduate Scholarship during his Ph.D. training; and the International Congress on Schizophrenia Research, Young Investigator Award. He has been a Director of Delivra Corp. December 21, 2015. He served as a Director of Whiteknight Acquisitions III Inc. since December 21, 2015. Dr. Gabriele received a B.Sc from the University of Toronto, with M.Sc. and Ph.D. degrees from McMaster University. Dr. Gabriele's Ph.D. training was conducted under Dr. R.K. Mishra, focusing on molecular pharmacology/neuroscience and its implications in psychiatric and neurological disorders.
Joe's compensation has been consistent with company performance over the past year.
Joe's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Delivra management team is about average.
Chief Financial Officer
Chief Marketing Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Delivra board of directors is about average.
Delivra Corp., a specialty biotechnology company, develops transdermal delivery system platform that shuttles pharmaceutical and natural molecules through the skin. It manufactures and sells a range of natural topical creams for joint and muscle pain, nerve pain, varicose veins, and wound healing under the LivRelief brand name, as well as for sports performance under the LivSport brand name. The company sells its products in pharmacies, grocery chains, and independent health food stores in Canada, as well as online at livrelief.com in Canada and the United States. Delivra Corp. is headquartered in Hamilton, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.